KB 95 (Sandoz) is a new derivative of the pyrazolone series which has certain pharmacological similarities to phenylbutazone (Figure) , though with a reported lower incidence of gastro-intestinal ulceration in the guinea-pig. Analgesic and anti-inflammatory pro- perties have been demonstrated in mice. It is also said to have a weak antispasmodic effect on smooth muscle and to reduce emotional tension in the rat. In contradistinction to phenylbutazone, however, it has a pharmacologically demonstrable antiserotonin effect in the rat. As no clinical report is available, we present the results of a pilot trial in a small group of patients.
Material
A course of KB 95 was given to thirty patients: eighteen with rheumatoid arthritis, nine with ankylosing spondylitis, and three with osteo-arthritis. Five of the patients with rheumatoid arthritis were admitted to hospital and received 7 to 14 days' therapy. The thirteen out-patients received therapy for 1 month. The patients were selected at random, and all had had uncomplicated disease for at least one year with classical clinical and radiological features. Sheep-cell agglutination and latex-fixation tests were positive in twelve of the eighteen rheumatoid patients. Most had received analgesics for several months and had definite opinions as to their value. Method The out-patients received 300 mg. KB 95 three times a day for 1 month. They were asked to compare the effect with that obtained from other analgesics, in particular, salicylates, phenylbutazone, and paracetamol. Pain, stiffness, loosening-up time, comments on general health, capacity for physical activity, and side-effects were noted. Haemoglobin, white cell counts, urine, and protein flocculation and turbidity tests were carried out regularly. The in-patients, who all had rheumatoid arthritis, were assessed twice-weekly by standard jewellers' rings, strength of grip, and joint tendemess, and weekly by erythrocyte sedimentation rate. The patients also kept a daily diary of their own estimates of pain, stiffness, and loosening-up time. All measurements were carried out by one observer only (P.B.). No apparent clinical effect was accepted as due to the drug unless a deterioration occurred on its withdrawal.
Results
Rheumatoid Arthritis.-Ten of the eighteen patients had no change in their symptoms, one reported an increase in joint pain, and seven noted symptomatic improvement. Three patients compared the effect with phenylbutazone (100 mg.) and considered the latter to be more efficient on a tabletfor-tablet basis, three found the relief similar to that obtained from aspirin (300 mg.), and four found the effect about the same as that of paracetamol (0 5-1 g.).
Only Osteo-Arthritis.-Two of the three patients had severe involvement of the knees and one had mild generalized disease. None noted any symptomatic improvement.
Side-Effects.-These occurred in six patients (Table) : four with rheumatoid arthritis complained of dyspepsia (two of whom had similar symptoms on soluble aspirin) and one noted a sensation of abdominal distension. One patient with ankylosing spondylitis reported mental irritability.
Discussion
The symptomatic relief obtained from one capsule of KB 95 (300 mg.) was less than that from phenylbutazone (100 mg.) and approximately the same as that from aspirin (300 mg.) or paracetamol (0-5-1 g. Concluimos que esta substancia no ofrece ventaja inmediata sobre la aspirina o el paracetamol y que, a pesar de ser un derivado de pirazolona, no se la puede comparar en su efecto terapeutico a la fenilbutazona.
